Mesenchymal stem cells (MSCs) are a type of non-controversial, adult stem cell that prefers to differentiate into the specialized cells found in skeletal tissues, such as cartilage cells (chondrocytes), bone cells (osteoblasts), and fat cells (adipocytes). In contrast, stem cells derived from embryos are capable of developing into all the different types of cells found in our body, which makes them more versatile than MSCs, but also more controversial. Induced pluripotent stem cells also exhibit greater pluripotency, but as modified cells, they come with a greater set of regulatory challenges. [Read more…]
Mesenchymal Stem Cells (MSCs)
Mesenchymal stem cells (MSCs) are a well-characterized population of adult stem cells that can differentiate into a variety of cell types (chondrocytes, osteoblasts, adipocytes, myocytes, and more).
Do You Know The 5 Types Of Stem Cells?
As you start to learn about stem cells, one of the most common questions to have is, “What types of stem cells exist?” There is not an agreed-upon number of stem cell types, because one can classify stem cells either by differentiation potential (what they can turn into) or by origin (from where they are sourced). This post is dedicated to explaining the five types of stem cells, based on differentiation potential. [Read more…]
RoosterBio Releases RoosterGEM™, Cell and Gene Therapy’s First Complete Transduction Medium
RoosterGEM™, a complete genetic engineering medium, empowers product developers to realize up to four-fold increased transduction efficiency in primary cells, and achieve a greater than 50% reduction in overall gene transfer cost.
Frederick, MD, May 20, 2021 – RoosterBio Inc., a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks and hMSC bioprocess systems for cell and gene therapy product developers, today announced the launch of its product RoosterGEM™, a stand-alone, complete gene transfer medium that is optimized to remove key challenges in primary cell genetic modification. [Read more…]
Landmark MSC Trial for Parkinson’s Disease Authorized by U.S. FDA
April 28, 2021, SUGAR LAND, Texas — Houston-area non-profit Hope Biosciences Stem Cell Research Foundation (HBSCRF) has received FDA authorization for a Phase II double-blind placebo controlled clinical trial to assess the efficacy and safety of multiple intravenous infusions of autologous adipose-derived mesenchymal stem cells to improve activities of daily living and quality of life in subjects with Parkinson’s Disease.
The trial is the first globally to administer pure adipose-derived mesenchymal stem cells to Parkinson’s patients in such high quantities over repeat treatments. Twenty-four patients will be randomized to receive six intravenous infusions of 200 million stem cells each. [Read more…]
